PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of springeropenLink to Publisher's site
European Journal of Pediatrics
 
Eur J Pediatr. 2010 October; 169(10): 1195–1199.
Published online 2010 April 23. doi:  10.1007/s00431-010-1200-0
PMCID: PMC2926442

Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome

Abstract

The aim of this study was to assess the prevalence of congenital heart defects (CHDs) and persistent pulmonary hypertension of the neonate (PPHN) in children with Down syndrome (DS) and to assess its impact on neonatal factors. It was a prospective study of a birth cohort of children with DS born between 2003 and 2006 registered by the Dutch Paediatric Surveillance Unit (DPSU). A CHD occurred in 43% of 482 children with trisomy 21. Atrioventricular septal defect was found in 54%, ventricular septal defect in 33.3% and patent ductus arteriosus in 5.8%. The incidence of PPHN in DS was 5.2%, which is significantly higher than the general population (p < 0.001). The reported mortality in newborns with DS was overall 3.3% and was still significant higher in children with a CHD versus no CHD (5.8% versus 1.5%) (p = 0.008). The presence of CHD in children with DS had no influence on their birth weight, mean gestational age and Apgar score. In neonates with DS, we found not only a 43% prevalence of CHD, but also a high incidence of PPHN at 5.2%. Early recognition of the cardiac condition of neonates with DS seems justified.

Keywords: Down syndrome, Prevalence, Persistent pulmonary hypertension of the neonate, Congenital heart defects, Neonate

Introduction

Down syndrome (DS) is the most common autosomal chromosome anomaly, affecting 16 out of every 10,000 live births in the Netherlands [19]. DS is frequently associated with congenital heart defects (CHD). Indeed CHDs are considered to be the most important clinical phenomenon of DS highly relevant to morbidity and decisive in infant mortality [16]. Over recent decades, there has been a substantial increase in the life expectancy of children with DS in general with an improvement in average life expectancy from 12 years in the 1940s to 60 years nowadays [16]. This increase in life expectancyhas mainly been due to the successful early surgical treatment of CHD in children with DS [5, 9, 10, 16].

Atrio-ventricular septal defect (AVSD), ventricular septal defect (VSD) and atrial septal defect (ASD) are the most common forms of CHD and recent reports have shown that the distribution of CHDs in children with DS may vary with ethnicity [3, 4, 7, 8, 14, 15, 17, 20].

In addition, Shah et al. have recently identified persistent pulmonary hypertension of the neonate (PPHN) in 24 out of 175 children with DS retrospectively; this increased prevalence in children with DS has not previously been identified as a specific problem among children with DS [13].

In the present study, we describe the prevalence of CHDs in neonates with DS in the Netherlands, determine the incidence of PPHN in this population and analyse the effect of a CHD on other neonatal factors.

Patients and methods

Our study includes all live births of children born between January 1, 2003 and December 31, 2006 who were diagnosed with DS and were reported to the Dutch Paediatric Surveillance Unit (DPSU). The DPSU is a national registry used by paediatricians to report various paediatric disorders, including DS. For each DS case reported to the DPSU, a questionnaire was sent to the attending pediatrician. The completed forms were returned to the Down Syndrome Study Group at the VU University Medical Center, Amsterdam. The method and details of the data collection have already been described earlier, and in 2003 the response rate for the DPSU was 96% and the overall response rate between 2003 and 2006 was 93.3% [19].

The diagnosis of DS was made in 91% in the first 7 days of life in the Netherlands, and most questionnaires were returned within the first 3 months after birth. In the Netherlands, 20% of the population under the age of 18 is from an ethnic minority background [19].

Only children with a karyotype analysis (antenatal or postnatal) were included. To ensure the homogeneity of the children with DS, all children with DS due to mosaicism or translocation were excluded. Children with DS for whom information regarding their cardiac status was absent or incomplete were also excluded. The Dutch DS screening program carries out an echocardiogram within the first 3 months of birth. We used the following items in the questionnaire for the analyses: sex, chromosomal analysis, ethnicity, cardiac evaluation, birth weight, gestational age of birth, 5-min Apgar score and the presence of PPHN. The diagnosis of PPHN was based on a clinical assessment and echocardiogram in the first week of life performed by neonatologists or paediatric cardiologists who answered the questionnaires. PPHN is defined, if the pulmonary pressure exceeds the systemic pressure, as being present a right-to-left shunt and is diagnosed by echocardiography. The use of a high percentage of oxygen is needed usually without a reaction on 100% oxygen and a difference in oxygen saturation measured pre-ductal and post-ductal, when a PDA is present [1, 13, 18]. Secundum ASD and persistent foramen ovale (PFO) were excluded as a CHD.

Statistical analysis

The binomial test was used to compare the prevalence of CHD and PPHN in children with DS and the Dutch reference population, respectively. We tabulated the frequency of CHD and the combinations of CHDs. Statistical comparisons of birth weight and gestational age for children with DS with and without CHD were made with independent sample t tests. Because of the influence of the gestational age on birth weight, we corrected birth weight for gestational age by using a multiple regression model. We used the Mann–Whitney test to compare non-parametric variables (e.g. Apgar score) and the Chi-square test for paired comparison of properties (e.g. asphyxia, ethnicity and mortality). Statistical analysis was performed with SPSS 16.0 statistical software. A p value of <0.05 was considered significant.

Results

Study group

The DPSU registered 820 children with DS who were born between January 1, 2003 and December 31, 2006. A total of 630 questionnaires were returned by the DPSU, and of these, 482 included complete data regarding the cardiac status. A CHD was reported in 207 (43%) of the children with trisomy 21, which is significantly higher than the prevalence of CHD in the Dutch reference population (0.62%, p < 0.001) [12] (Fig. 1).

Fig. 1
Children with Down syndrome (DS) in the Netherlands born in the period January 1, 2003 to December 31, 2006 with and without congenital heart defect (CHD). Asterisk (*) one child had a combination of trisomy 21 and triple X (0.2%)

In 2003, the prevalence in the Netherlands of live and still-born children with DS was 26.8 per 10,000 pregnancies compared with 16 newborns with DS per 10,000 live births; there were no exact data on the prevalence of CHD in these stillborn children with DS [19].

Congenital heart defects

The data for CHD in children with DS are summarized in Table 1. In 2.4% (n = 5) of children, the CHD did not match any of the categories mentioned and thus these were thus counted as ‘other’. In 28.9% (n = 60) of the children, there were multiple cardiac defects (i.e. a combination of defects).

Table 1
Children with Down syndrome and a congenital heart defect (CHD; total n = 207)

Ethnicity

The ethnic background of children with DS was reported for 404 children and was predominantly Caucasian (77.5%, n = 313). Of these Caucasian children, 127 (40.6%) had a CHD. In 22.5% (n = 91), one or both of the parents came from an ethnic minority group most of which were from a Moroccan, Turkish or Antillean background. Within this ethnic group, 42.9% (n = 39) of the children with DS had a CHD. There were no differences in the distribution of CHDs neither in the ethnic group compared to the Caucasian group nor within the ethnic subgroups. The data on ethnicity were missing for 78 children with DS.

Persistent pulmonary hypertension of the neonate

PPHN was reported in 25 children with DS; an incidence of 5.2%, which is significant, elevated in comparison with the reported 0.1% in the general population (p < 0.001) [18]. Table 2 shows the distribution of CHDs in children with DS and PPHN of which 36% (n = 9) of the children had no CHD.

Table 2
Children with Down syndrome and persistent pulmonary hypertension of the neonate (PPHN) (n = 25) and the distribution of a concomitant congenital heart defect (CHD)

Neonatal variables

The presence or absence of a CHD had no significant relationship with birth weight and gestational age. The mean birth weights of the children with and without a CHD were 2,926 and 3,013 g, respectively (95% CI; −270–87), and the mean gestational age of the children with DS with and without CHD were 38.0 and 38.3 weeks, respectively (95% CI; −0.64–0.16). The median of the Apgar score at 5 min was nine in children with DS both with and without a CHD. Also, the frequency of asphyxia (Apgar score <6) in children with DS with a CHD did not differ from those without a CHD (1.6% versus 2.8%) (p = 0.39).

Mortality

The reported mortality among the neonates with DS was16 out of 482 (3.3%). Most of the 16 children with DS died within 30 days of birth (n = 11), one died on day 39 and another on day 318 following birth. The data of the remaining three non-survivors are missing. Among the neonates with DS who died, 12 children had a CHD (12 out of 207 CHD children (5.8%)) and four children had no CHD (4 out of 275 non CHD children, 1.5%). This was a significant difference in mortality among the children with DS with and without a CHD, (p = 0.008). The causes of death in the 12 children with DS and a CHD were as follows: respiratory distress (n = 3, all AVSD), neonatal infection (n = 2, AVSD and aortic regurgitation), asphyxia (n = 1, AVSD), post cardiac operation (n = 1, AVSD) and necrotizing enterocolitis (n = 1, VSD). In four children, the cause of death was not documented in the questionnaires (three AVSD and one PDA). The four children without a CHD died as a result of asphyxia, respiratory distress and infection, respectively, and one cause of death was unknown.

Discussion

This is the first large-scall study in the Netherlands regarding CHDs in children with DS. We found a prevalence of CHDs of 43%, which is concordant with the prevalence presented in the literature of 44–58% [3, 4, 7, 8, 14, 15, 17, 20], AVSD (54%) was the most commonly occurring CHD in children with DS in our study. In our study, early diagnostic echocardiography was performed. Secundum ASD and persistent foramen ovale (PFO) were excluded as a CHD because a small secundum ASD is sometimes difficult to differentiate from a persistent foramen ovale, and the study design did not include follow-up to provide sufficient clarity about ASD versus PFO [9, 16]. This could have caused an underestimation of the prevalence of CHD in our study. The early diagnostic procedure was used to make an early assessment of cardiac anatomy and in case of a significant defect to perform early intervention and to prevent pulmonary arterial hypertension in defects with a left to right shunt.

The inclusion of various cardiac defects and the use of different terminology in studies with children with DS made it difficult to compare these studies with our results. For instance, Stoll et al. did not report ASD as a CHD as well, which may explain why PDA is one of the three most prevalent defects in their study [7, 10, 14, 17]. In our study, there was no significant difference in the distribution of CHD according to ethnicity, as the subgroups were too small.

Freeman et al. reported in their study in the United States of America that black infants with DS had an AVSD more frequently than whites and that Hispanic infants with DS had an AVSD less frequently than whites [4]. In Chinese children with DS and a CHD, VSD was seen in 38% and AVSD in 25% [7]. AVSDs accounted for only 9% of the CHDs in Mexican children with DS, while ASD, VSD, and PDA were most common. This study however began at the age 13, so the mortality prior to the age of 13 may explain their distribution of CHDs [3].

Another relevant phenomenon which, to our knowledge, had not previously been appreciated and as such was not included in DS guidelines [2, 6] was the significantly increased incidence of PPHN in neonates with DS (5.2%) we found in our study. This corresponds with Cua et al. who estimated the incidence of idiopathic PPHN in neonates with DS between 1.2% and 6.6%, which is much higher than the reported overall incidence of 0.1% in the general population [1]. In our study, only seven children (28%) had an AVSD, and in these children, we cannot exclude a relationship with the development of PPHN and nine (36%) children with DS and PPHN did not have a CHD. In addition Shah et al. found no serious structural heart defect in 70% of children with DS and PPHN [13]. PPHN should be distinguished from another type of pulmonary hypertension, originating from a cardiac defect that permits left-to-right shunting and requires some period of time to be clinically detected. The newborn children with DS, who develop PPHN, are by contrast symptomatic just after birth [1, 13, 18].

Wren et al. found no clinical signs in the first weeks in some children with DS, with major cardiac malformations and associated pulmonary hypertension, even in some who progressed to irreversible pulmonary vascular disease [21]. A normal neonatal examination in children with DS does not therefore exclude a serious CHD [11]. This corresponds with our findings and emphasizes the importance of an early echocardiography of neonates with DS to detect any CHD and to determine the possible risk of developing pulmonary hypertension, as supported by the DS health care guidelines published by the American Academy of Pediatrics and the Down Syndrome Medical Interest Group of the United Kingdom and Ireland [2, 6]. Because of the high incidence of a significant CHD in children with Down syndrome, the early recognition of CHD can lead to the optimal management of the defect. The surgical correction of significant defects usually takes place at the age of 2–4 months, though this happens earlier in certain cases (e.g. TOF) [9, 10].

In our study, basic neonatal characteristics, Apgar scores, birth weight and gestational age were not different in children with DS with and without CHD. This is in concords with Frid et al. who analysed the influence of CHD on these neonatal issues in 304 neonates with DS and also found no difference between those with and without CHD [5].

In the past decade, research has shown that neonatal mortality in DS appears to be becoming less dependent on CHDs and more often caused by neonatal pathology such as asphyxia, low birth weight and prematurity, as in the general population [5, 19]. With regard to mortality, we should emphasize that with the exception of one child who died following a cardiac operation, the presence of a CHD was not responsible for reported mortality in children with DS in our recent study.

Our study has several limitations. Because of its retrospective design, we used data from questionnaires completed by paediatricians and have no on follow-up data. Furthermore, there was a sample bias since we could not use the data of all 820 children with DS who were registered by the DPSU, 630 (76.8%) questionnaires were returned and not all questionnaires relating to children with trisomy 21 had complete data on cardiac status. On the other hand, the fall out cases were distributed between both the CHD and non-CHD children with DS.

Though the definition of PPHN was not specifically defined, diagnosis was based on the clinical assessment and an echocardiogram performed by the neonatologists and pediatric cardiologists who answered the questionnaires. It was impossible to draw a definitive conclusion on the exact role of the AVSD in the seven children with an AVSD in relation to the cause of the pulmonary hypertension; nevertheless, there were at least 18 other children (3.7% of total) with PPHN that was not related to a CHD, which is still a high level.

In conclusion, we have demonstrated a 43% prevalence of CHD in neonates with DS and a significantly increased and elevated incidence of PPHN in neonates with DS (5.2%) compared to the general population. Early recognizing the cardiac condition of neonates with DS seems justified. CHDs had no relationship with neonatal factors such as gestational age, Apgar score and birth weight of children with DS. There are no conflicts of interests

Acknowledgments

There are no conflicts of interests.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Cua CL, Blankenship A, North AL, et al. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol. 2007;28:250–254. doi: 10.1007/s00246-006-0011-6. [PubMed] [Cross Ref]
2. Cunnif C, Frias JL, Kaye C, et al. Health supervision for children with Down syndrome, American Academy of Pediatrics. Pediatrics. 2001;107:442–449. doi: 10.1542/peds.107.2.442. [PubMed] [Cross Ref]
3. Rubens FJ, Pozzo MB, Hach JLP, et al. Heart malformations in children with Down syndrome. Rev Esp Cardiol. 2003;56:894–899. doi: 10.1157/13051617. [PubMed] [Cross Ref]
4. Freeman SB, Bean LH, Allen EG, et al. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genet Med. 2008;10:173–180. doi: 10.1097/GIM.0b013e3181634867. [PubMed] [Cross Ref]
5. Frid C, Drott P, Otterblad OP, et al. Maternal and neonatal factors and mortality in children with Down syndrome born in 1973–1980 and 1995–1998. Acta Paediatr. 2004;93:106–112. doi: 10.1111/j.1651-2227.2004.tb00683.x. [PubMed] [Cross Ref]
6. Guidelines for basic essential medical surveillance. The Down's syndrome medical interest group UK and Ireland. Available at http://www.dsmig.org.uk/publications/guidelines.html. Accessed 29 January 2010.
7. Jacobs EG, Leung MP, Karlberg J. Distribution of symptomatic congenital heart disease in Hong Kong. Pediatr Cardiol. 2000;21:148–157. doi: 10.1007/s002469910025. [PubMed] [Cross Ref]
8. Jaiyesimi O, Baichoo V. Cardiovascular malformations in Omani Arab children with Down's syndrome. Cardiol Young. 2007;17:166–171. doi: 10.1017/S1047951107000078. [PubMed] [Cross Ref]
9. Kortenhorst MSQ, Hazekamp MG, Rammeloo LAJ, et al. Complete atrioventricular septal defect in children with Down´s syndrome: good results of surgical correction at younger and younger ages. Ned Tijdschr Geneeskd. 2005;149:589–593. [PubMed]
10. Lange R, Guenther T, Busch R, et al. The presence of Down syndrome is not a risk factor in complete atrioventricular septal defect repair. J Thorac Cardiovasc Surg. 2007;134:304–310. doi: 10.1016/j.jtcvs.2007.01.026. [PubMed] [Cross Ref]
11. McElhinney DB, Straka M, Goldmuntz E, et al. Correlation between abnormal cardiac physical examination and echocardiographic findings in neonates with Down syndrome. Am J Med Genet. 2002;113:238–241. doi: 10.1002/ajmg.10803. [PubMed] [Cross Ref]
12. National Institute for Public Health and Environment , Rijks Instituut voor Volksgezondheid en Milieu (RIVM), National Dutch data collection on Health and Environment. Available at http://www.rivm.nl/vtv/object_document/o1340nl18479.html. Accessed 29 January 2010
13. Shah PS, Hellmann J, Adatia I. Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. J Perinat Med. 2004;32:168–170. doi: 10.1515/JPM.2004.030. [PubMed] [Cross Ref]
14. Stoll C, Alembik Y, Dott B, et al. Study of Down syndrome in 238, 942 consecutive births. Ann Génét. 1998;41:44–51. [PubMed]
15. Torfs CP, Christianson RE. Anomalies in Down syndrome individuals in a large population-based registry. Am J Med Genet. 1998;77:431–438. doi: 10.1002/(SICI)1096-8628(19980605)77:5<431::AID-AJMG15>3.0.CO;2-J. [PubMed] [Cross Ref]
16. Vis JC, Duffels MGJ, Winter MM, et al. Down syndrome: a cardiovascular perspective. J Intellect Disabil Res. 2009;53:419–425. doi: 10.1111/j.1365-2788.2009.01158.x. [PubMed] [Cross Ref]
17. Wahab AA, Bener A, Sandridge AL, et al. The pattern of Down syndrome among children in Qatar: a population-based study. Birth Defects Res A Clin Mol Teratol. 2006;76:609–612. doi: 10.1002/bdra.20290. [PubMed] [Cross Ref]
18. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000;105:14–20. doi: 10.1542/peds.105.1.14. [PubMed] [Cross Ref]
19. Weijerman ME, Furth AM, Vonk Noordegraaf A, et al. Prevalence, neonatal characteristics and first-year mortality of Down syndrome: a national study. J Pediatr. 2008;152:15–19. doi: 10.1016/j.jpeds.2007.09.045. [PubMed] [Cross Ref]
20. Wells GL, Barker SE, Finley SC, et al. Congenital heart disease in infants with Down's syndrome. South Med J. 1994;87:724–727. doi: 10.1097/00007611-199407000-00010. [PubMed] [Cross Ref]
21. Wren C, Richmond S, Donaldson L. Presentation of congenital heart disease in infancy: implications for routine examination. Arch Dis Child Fetal Neonatal Ed. 1999;80:F49–F53. doi: 10.1136/fn.80.1.F49. [PMC free article] [PubMed] [Cross Ref]

Articles from Springer Open Choice are provided here courtesy of Springer